Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

Keyphrases

• Mutational Analysis 100%
• Atypical Proliferative Serous Tumor 100%
• Peritoneal Implants 100%
• Serous Borderline 100%
• BRAF mutation 87%
• Serous Borderline Tumor 87%
• KRAS mutation 75%
• Tumor Implantation 50%
• Primary Ovarian Cancer 25%
• VE1 Immunohistochemistry 25%
• Denmark 12%
• Surrogate Marker 12%
• Primary Tumor 12%
• Advanced Stage Disease 12%
• Mutation Status 12%
• DNA Amplification 12%
• Peritoneum 12%
• Tumor Registry 12%
• V600E-BRAF 12%
• Wild-type KRAS 12%
• Insufficient Tissue 12%

Medicine and Dentistry

• Implant 100%
• Tumor 100%
• Mutational Analysis 100%
• Ovarian Tumor 18%
• Immunohistochemistry 18%
• Disease Marker 9%
• Primary Tumor 9%
• Gene Amplification 9%
• Peritoneum 9%
• Diseases 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Implant 100%
• Borderline State 63%
• Ovary Tumor 18%
• Disease Marker 9%
• Primary Tumor 9%
• Diseases 9%